Phase 1/2a, open‐label, multicenter study of <scp>RM</scp>‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma
David M. Cognetti(Thomas Jefferson University), Ann M. Gillenwater(The University of Texas MD Anderson Cancer Center), D. McDonald, Mary J. Fidler, Samith T. Kochuparambil(Minnesota Oncology), Nilesh Vasan(University of Oklahoma Health Sciences Center), Frank E. Mott(The University of Texas MD Anderson Cancer Center), Kosuke Ishida(Rakuten (Japan)), Miguel García‐Guzmán(Rakuten (United States)), Patrick K. Ha(University of California, San Francisco), Kerstin Stenson(Rush University Medical Center), Jennifer M. Johnson(Thomas Jefferson University), Mohammad Razaq(University of Oklahoma Health Sciences Center), John Campana(Dermatology Specialists), Grace Mann(San Mateo Medical Center), Merrill A. Biel(San Mateo Medical Center), Joseph Curry(Thomas Jefferson University)
Cited by 170
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
|Nature Medicine|2018|1k
Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas
|Science Translational Medicine|2015|502